AbbVie Inc. (NYSE: ABBV) and Cerevel Therapeutics (NASDAQ: CERE) have announced a definitive agreement in which AbbVie will acquire Cerevel Therapeutics. The transaction, valued at approximately $8.7 billion, is a strategic move that enhances AbbVie’s neuroscience portfolio by adding a robust pipeline of multiple clinical-stage and preclinical candidates. These candidates hold potential across several diseases, […]
AbbVie Inc. and ImmunoGen Inc. have entered into a definitive agreement, marking a significant move in the pharmaceutical industry. AbbVie will acquire ImmunoGen, including its flagship cancer therapy ELAHERE (mirvetuximab soravtansine-gynx), for $31.26 per share in cash, totaling an equity value of approximately $10.1 billion. ELAHERE: A Breakthrough in Cancer Treatment The acquisition is a […]
REGENXBIO Inc. has disclosed new findings from its Phase II ALTITUDE trial, focusing on ABBV-RGX-314 as a gene therapy for diabetic retinopathy (DR) treatment. This announcement comes ahead of a detailed presentation set for the American Academy of Ophthalmology meeting by Dr. Mark Barakat of Retinal Consultants of Arizona. ALTITUDE Trial and Diabetic Retinopathy: The […]
AbbVie and Scripps Research institute’s division Calibr have announced a broadened strategic collaboration targeted at developing preclinical and early-stage clinical assets across a host of therapeutic areas such as immunology, oncology, and neuroscience. The extended partnership which aligns with AbbVie’s core areas of interest builds upon the company’s 2019 partnership with Scripps Research. Thomas Hudson, […]
Caplin Steriles, a subsidiary of India’s Caplin Point Laboratories, has obtained final approval from the US Food and Drug Administration (FDA) for its generic version of AbbVie’s NIMBEX injection. The approved drug, Cisatracurium Besylate Injection USP, is expected to be a significant player in a market that, according to IQVIA (IMS Health), generated US sales […]
Danish biotech company Genmab has secured accelerated approval for EPKINLY (epcoritamab-bysp) from the US Food and Drug Administration (FDA) for the treatment of relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in adults. The T-cell engaging bispecific antibody is indicated for diffuse large B-cell lymphoma resulting from indolent lymphoma, and high-grade B‑cell lymphoma, following […]
RINVOQ FDA approval for nr-axSpA : AbbVie has bagged approval for its selective JAK inhibitor RINVOQ (upadacitinib 15 mg, once daily) from the US Food and Drug Administration (FDA) for the treatment of adults having active non-radiographic axial spondyloarthritis (nr-axSpA). The approval from the FDA is for nr-axSpA in people with objective signs of inflammation […]
AbbVie has acquired DJS Antibodies, a privately-held UK-based biotech company, in an all-cash transaction valued at approximately $255 million, in a move to further strengthen its immunology pipeline. DJS Antibodies discovers and develops antibody drugs that target difficult-to-drug disease-causing proteins like G protein-coupled receptors (GPCRs). Through the transaction, AbbVie has acquired DJS-002, which is DJS […]
Harpoon Therapeutics has bagged fast track designation for HPN217 from the US Food and Drug Administration (FDA) for the treatment of certain patient population with relapsed, refractory multiple myeloma (RRMM). HPN217 is a B-cell maturation antigen (BCMA) targeting Tri-specific T cell Activating Construct (TriTAC). Its fast track designation is for relapsed, refractory multiple myeloma patients […]
Natco Pharma Limited said that a US District Court has given a decision in favor of Pharmacyclics, a subsidiary of AbbVie, the brand owner of Imbruvica (ibrutinib) in a PIV litigation that involved the cancer drug. The Indian pharma company said that it will review the judgment and assess all options for appealing the judgment, […]
